TW201307295A - 咪唑衍生物的製造方法 - Google Patents

咪唑衍生物的製造方法 Download PDF

Info

Publication number
TW201307295A
TW201307295A TW101121273A TW101121273A TW201307295A TW 201307295 A TW201307295 A TW 201307295A TW 101121273 A TW101121273 A TW 101121273A TW 101121273 A TW101121273 A TW 101121273A TW 201307295 A TW201307295 A TW 201307295A
Authority
TW
Taiwan
Prior art keywords
compound
mixture
added
stirred
mmol
Prior art date
Application number
TW101121273A
Other languages
English (en)
Chinese (zh)
Inventor
Yoichi Kawabata
Yasuhiro Sawai
Kazuaki Kanno
Naotaka Sawada
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46458578&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW201307295(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of TW201307295A publication Critical patent/TW201307295A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28Antiandrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32Antioestrogens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW101121273A 2011-06-15 2012-06-14 咪唑衍生物的製造方法 TW201307295A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2011133712 2011-06-15

Publications (1)

Publication Number Publication Date
TW201307295A true TW201307295A (zh) 2013-02-16

Family

ID=46458578

Family Applications (1)

Application Number Title Priority Date Filing Date
TW101121273A TW201307295A (zh) 2011-06-15 2012-06-14 咪唑衍生物的製造方法

Country Status (27)

Country Link
US (2) US9278938B2 (enExample)
EP (1) EP2721010B1 (enExample)
JP (1) JP6082353B2 (enExample)
KR (1) KR20140028069A (enExample)
CN (1) CN103608334B (enExample)
AR (1) AR086926A1 (enExample)
AU (1) AU2012270496A1 (enExample)
BR (1) BR112013030888A2 (enExample)
CA (1) CA2838971C (enExample)
CL (1) CL2013003492A1 (enExample)
CO (1) CO6852075A2 (enExample)
CR (1) CR20130655A (enExample)
DO (1) DOP2013000287A (enExample)
EA (1) EA201490019A1 (enExample)
EC (1) ECSP14013128A (enExample)
ES (1) ES2554454T3 (enExample)
IL (1) IL229566A0 (enExample)
MA (1) MA35809B1 (enExample)
MX (1) MX2013014009A (enExample)
PE (1) PE20141326A1 (enExample)
PH (1) PH12013502567A1 (enExample)
SG (1) SG195036A1 (enExample)
TN (1) TN2013000481A1 (enExample)
TW (1) TW201307295A (enExample)
UY (1) UY34130A (enExample)
WO (1) WO2012173280A1 (enExample)
ZA (1) ZA201308884B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016054129A1 (en) * 2014-09-30 2016-04-07 Stc.Unm Graphene-based inorganic-organic hybrid materials and separation of racemic mixtures
US20200033307A1 (en) * 2018-07-25 2020-01-30 Honeywell International Inc. Method of determining an amount of water in a sample using a derivative of imidazole and a hydrogen halide donor
KR102253950B1 (ko) * 2019-07-24 2021-05-20 (주)에니켐텍 신규한 메데토미딘 제조방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5832880A (ja) * 1981-08-24 1983-02-25 Isukura Sangyo Kk ハリントニンの部分合成方法
US6713632B1 (en) 1999-06-22 2004-03-30 Takeda Chemical Industries, Ltd. Process for the preparation of imidazole derivatives
PE20010781A1 (es) 1999-10-22 2001-08-08 Takeda Chemical Industries Ltd Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion
DE10031604A1 (de) 2000-06-29 2002-01-17 Consortium Elektrochem Ind Verfahren zur Herstellung von beta-Hydroxy- und beta-Aminocarbonylverbindungen
TWI306099B (en) 2000-11-17 2009-02-11 Takeda Chemical Industries Ltd Novel imidazole derivatives, production method thereof and use thereof
CN1289434C (zh) 2002-01-04 2006-12-13 皇家飞利浦电子股份有限公司 烧结体和电灯
US7662974B2 (en) * 2002-01-10 2010-02-16 Takeda Pharmaceutical Company Limited Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same
EP1394140A1 (de) * 2002-08-14 2004-03-03 Consortium für elektrochemische Industrie GmbH Enantioselektives Reformatsky-Verfahren zur Herstellung von optisch aktiven Alkoholen, Aminen und deren Derivaten
EP2164409B1 (en) 2007-06-29 2018-08-08 Atheromed, Inc. Atherectomy system

Also Published As

Publication number Publication date
ECSP14013128A (es) 2014-02-28
ZA201308884B (en) 2015-02-25
EA201490019A1 (ru) 2014-04-30
CN103608334A (zh) 2014-02-26
CA2838971C (en) 2019-07-30
AU2012270496A1 (en) 2013-12-19
JP6082353B2 (ja) 2017-02-15
CN103608334B (zh) 2015-12-23
US20140100373A1 (en) 2014-04-10
US10005780B2 (en) 2018-06-26
SG195036A1 (en) 2013-12-30
PH12013502567A1 (en) 2014-01-27
CO6852075A2 (es) 2014-01-30
CL2013003492A1 (es) 2014-07-18
DOP2013000287A (es) 2014-02-16
MX2013014009A (es) 2014-03-12
AR086926A1 (es) 2014-01-29
EP2721010B1 (en) 2015-09-09
TN2013000481A1 (en) 2015-03-30
CR20130655A (es) 2014-03-03
ES2554454T3 (es) 2015-12-21
CA2838971A1 (en) 2012-12-20
UY34130A (es) 2013-01-31
EP2721010A1 (en) 2014-04-23
PE20141326A1 (es) 2014-10-16
JP2014520066A (ja) 2014-08-21
BR112013030888A2 (pt) 2017-03-21
MA35809B1 (fr) 2014-12-01
US9278938B2 (en) 2016-03-08
WO2012173280A1 (en) 2012-12-20
US20160244454A1 (en) 2016-08-25
KR20140028069A (ko) 2014-03-07
IL229566A0 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
JP2020512370A (ja) 6−(シクロプロパンアミド)−4−((2−メトキシ−3−(1−メチル−1h−1,2,4−トリアゾール−3−イル)フェニル)アミノ)−n−(メチル−d3)ピリダジン−3−カルボキシアミドの製造方法
CN104718216B (zh) 制备头孢洛林酯的新方法
JP2013501024A (ja) 薬学的に活性な化合物の製造方法
JP7644009B2 (ja) 3-メチル-1,2,4-チアジアゾール-5-カルボヒドラジドまたはそのメチル-d3重水素化形態の合成
CN104994733B (zh) 制备4‑氨基‑5‑氟‑3‑氯‑6‑(取代的)吡啶甲酸酯的方法
TW202233569A (zh) 製備3—氟—5—(((1S,2aR)—1,3,3,4,4—五氟—2a—羥基—2,2a,3,4—四氫—1H—環戊[cd]茚—7—基)氧基)苯甲腈之方法
JP2007536325A (ja) 新規イミダゾール誘導体、それらの製造方法、及び医薬組成物及び殺菌剤の製造用中間体としてのそれらの使用
JP7190438B2 (ja) ベンゾイル蟻酸化合物及びピリダジン化合物の製造方法
TW201307295A (zh) 咪唑衍生物的製造方法
CN110028451B (zh) 一种全取代吡唑衍生物制备方法
CN1639130B (zh) 制备稠合咪唑化合物的方法、稳定形式的里福马斯基试剂及其制备方法
Murphy et al. A radical based addition–elimination route for the preparation of indoles
JP2023525772A (ja) N-ブチルオキシカルボニル-3-(4-イミダゾール-1-イルメチルフェニル)-5-イソ-ブチルチオフェン-2-スルホンアミドの合成のためのプロセス
JP2013514344A (ja) 4−ブロモメチル−[1,1’−ビフェニル]−2’−カルボニトリルの調製方法
TW202317512A (zh) 取代的吲哚衍生物之合成
CN113214224B (zh) 多取代3-亚甲基异吲哚啉酮衍生物的制备方法
JP2010077077A (ja) N−ペンタノイル−n−[2’−(1h−テトラゾール−5−イル)ビフェニル−4−イルメチル]−l−バリンの製造方法
WO2018163818A1 (ja) トリアゾール化合物の製造方法
CN116635369A (zh) 制备烟酸衍生物的方法
EP4559903A1 (en) Production method for tafamidis or salt thereof
JPH0948778A (ja) 2−置換−3−アルコキシ−5−(ピロール−2−イル)フラン誘導体
TW202535810A (zh) 經取代苯基乙腈及經取代苯基醋酸之製備方法
JP2005047827A (ja) 3−クロロメチル−3−セフェム誘導体結晶の製造方法
CN102439010A (zh) 稠合三环磺酰胺的制备方法
HK1231059B (zh) 化合物的制备方法